1. Home
  2. ZETA vs TGTX Comparison

ZETA vs TGTX Comparison

Compare ZETA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zeta Global Holdings Corp.

ZETA

Zeta Global Holdings Corp.

HOLD

Current Price

$18.31

Market Cap

4.7B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.22

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZETA
TGTX
Founded
2007
1993
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.5B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
ZETA
TGTX
Price
$18.31
$31.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
4
Target Price
$26.25
$54.75
AVG Volume (30 Days)
5.0M
1.6M
Earning Date
11-04-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.78
Revenue
$1,224,703,000.00
$531,898,000.00
Revenue This Year
$30.55
$87.88
Revenue Next Year
$30.24
$48.75
P/E Ratio
N/A
$11.16
Revenue Growth
35.87
100.88
52 Week Low
$10.69
$25.28
52 Week High
$26.60
$46.48

Technical Indicators

Market Signals
Indicator
ZETA
TGTX
Relative Strength Index (RSI) 49.93 48.42
Support Level $17.24 $29.79
Resistance Level $19.96 $32.30
Average True Range (ATR) 0.77 1.09
MACD -0.05 0.03
Stochastic Oscillator 39.34 61.38

Price Performance

Historical Comparison
ZETA
TGTX

About ZETA Zeta Global Holdings Corp.

Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: